Fig. 2From: Safety and efficacy of sirolimus in recurrent intravenous leiomyomatosis, pulmonary benign metastatic leiomyomatosis, and leiomyomatosis peritonealis disseminata: a pilot studyAntitumor activity of sirolimus. A Changes in target lesions at the time of best response (n = 15). B Longitudinal changes in tumor size from baseline (n = 15). C Treatment exposure and response duration (n = 15)Back to article page